Dx Deals: Quest Closes PathAI Partial Acquisition and Strategic Alliance
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Congress reportedly set to pass a stripped-down version of the FDA user fees bill without the VALID Act component regulating LDTs.
On August 21, the FDA proposed new guidelines on charging for investigational drugs; here are the key highlights.
Revised final rule essentially disarms the threat of insurers having the advantage in out-of-network price disputes.
While the overall M&A market has been slow in 2022, Labcorp has been on a bit of an acquisitions binge.
In a surprise move, the e-retail giant announced it will close down its Amazon Care Primary Health Services for employees at the end of 2022.
While the rule is not yet final, it’s likely that labs will have to pay more in direct CLIA compliance expenses, starting in October.
While not nearly as robust as a year ago, diagnostic companies’ revenues held up surprisingly well in Q2 2022.
The agency is once more accepting pre-submissions for all in vitro diagnostic tests, not just those for COVID-19.
In July, ICATT took a major step toward equitable access to testing by enlisting two of the country’s leading COVID-19 PCR test providers.
It’s beginning to look like Illumina’s roll of the dice is going to come up snake eyes regarding the potential acquisition.